Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 527

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Perioperative Nivolumab in Resectable Lung Cancer

Open access
Cascone, Tina, Awad, Mark M., Spicer, Jonathan D., He, Jie, Lu, Shun, Sepesi, Boris, Tanaka, Fumihiro, Taube, Janis M., Cornelissen, Robin, Havel, Libor, Karaseva, Nina, Kuzdzal, Jaroslaw, Petruzelka, Lubos B., Wu, Lin, Pujol, Jean-Louis, Ito, Hiroyuki, Ciuleanu, Tudor-Eliade, de Oliveira Muniz Koch, Ludmila, Janssens, Annelies, Alexandru, Aurelia, Bohnet, Sabine, Moiseyenko, Fedor V., Gao, Yang, Watanabe, Yasutaka, Coronado Erdmann, Cinthya, Sathyanarayana, Padma, Meadows-Shropshire, Stephanie, Blum, Steven I., Provencio Pulla, Mariano·2024·New England Journal of Medicine

Abstract

BACKGROUND: Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients with resectable non-small-cell lung cancer (NSCLC). Perioperative treatment (i.e., neoadjuvant therapy followed by surgery and adjuvant therapy) with nivolumab may further improve clinical outcomes. METHODS: In this phase 3, randomized, double-blind trial, we assigned adults with resectable stage IIA to IIIB NSCLC to receive neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo every 3 weeks for 4 cycles, followed by surgery and adjuvant nivolumab or placebo every 4 weeks for 1 year. The primary outcome was event-free survival according to blinded independent review. Secondary outcomes were pathological complete response and major pathological response according to blinded independent review, overall survival, and safety. RESULTS: At this prespecified interim analysis (median follow-up, 25.4 months), the percentage of patients with 18-month event-free survival was 70.2% in the nivolumab group and 50.0% in the chemotherapy group (hazard ratio for disease progression or recurrence, abandoned surgery, or death, 0.58; 97.36% confidence interval [CI], 0.42 to 0.81; P<0.001). A pathological complete response occurred in 25.3% of the patients in the nivolumab group and in 4.7% of those in the chemotherapy group (odds ratio, 6.64; 95% CI, 3.40 to 12.97); a major pathological response occurred in 35.4% and 12.1%, respectively (odds ratio, 4.01; 95% CI, 2.48 to 6.49). Grade 3 or 4 treatment-related adverse events occurred in 32.5% of the patients in the nivolumab group and in 25.2% of those in the chemotherapy group. CONCLUSIONS: Perioperative treatment with nivolumab resulted in significantly longer event-free survival than chemotherapy in patients with resectable NSCLC. No new safety signals were observed. (Funded by Bristol Myers Squibb; CheckMate 77T ClinicalTrials.gov number, NCT04025879.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2311926

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 527

Metadata

Authors
Cascone, T., Awad, M. M., Spicer, J. D., He, J., Lu, S., Sepesi, B., Tanaka, F., Taube, J. M., Cornelissen, R., Havel, L., Karaseva, N., Kuzdzal, J., Petruzelka, L. B., Wu, L., Pujol, J.-L., Ito, H., Ciuleanu, T.-E., de Oliveira Muniz Koch, L., Janssens, A., Alexandru, A., Bohnet, S., Moiseyenko, F. V., Gao, Y., Watanabe, Y., Coronado Erdmann, C., Sathyanarayana, P., Meadows-Shropshire, S., Blum, S. I., & Provencio Pulla, M.
Venue
New England Journal of Medicine
Published
2024-05-16
Volume
390
Issue
19
Pages
1756-1769
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4396915845
Cited by
527
References
18
FWCI
134.21
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Perioperative Nivolumab in Resectable Lung Cancer. https://app.cochat.ai/papers/10.1056/nejmoa2311926
The paper
Cascone, T., Awad, M. M., Spicer, J. D., He, J., Lu, S., Sepesi, B., Tanaka, F., Taube, J. M., Cornelissen, R., Havel, L., Karaseva, N., Kuzdzal, J., Petruzelka, L. B., Wu, L., Pujol, J.-L., Ito, H., Ciuleanu, T.-E., de Oliveira Muniz Koch, L., Janssens, A., . . . Provencio Pulla, M. (2024). Perioperative Nivolumab in Resectable Lung Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2311926

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.